本帖最后由 老马 于 2012-1-13 21:20 编辑 & U2 |' b/ C5 y. s
3 r$ G5 V0 N8 z4 ^* n$ k3 x
爱必妥和阿瓦斯丁的比较8 g1 o7 d6 O c# Q( D
0 f" |9 h! A8 @% `9 lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ l6 H$ W$ y, F) U4 Y6 U. ]. f+ A; F
0 X/ u. B4 o6 d/ a4 B$ J
, `! X& C8 A( h) O/ Xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/1 p: v& _' `9 j" v
==================================================
( z# p' A8 H) R& G/ ^: C4 iOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) y+ ]0 R5 ?! _' _) ~6 Y( VPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! H2 @" F, T2 N/ Y# M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( E$ x) Q7 A/ f4 N: }. m+ k
|
显身卡
